On May 1, 2018 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, reported that it will host a conference call on Monday, May 7, 2018 at 5pm ET to discuss first quarter 2018 financial results and provide a corporate update (Press release, Ultragenyx Pharmaceutical, MAY 1, 2018, http://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-host-conference-call-first-quarter-2018-financial [SID1234525930]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live and replayed webcast of the call will be available through the company’s website at View Source To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 3748439. The replay of the call will be available for one year.

On May 1, 2018 TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, reported its participation in two upcoming investor conferences (Press release, TESARO, MAY 1, 2018, View Source [SID1234525929]). The two conferences are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Bank of America Merrill Lynch 2018 Healthcare Conference at the Encore Hotel in Las Vegas, Nevada on Tuesday, May 15, 2018. Tim Pearson, EVP and CFO of TESARO, will participate in an analyst-led moderated Q&A at 4:20 PM PT and in meetings with investors.

The Leerink Boston Biopharma Bus Tour on Thursday, May 17, 2018.Lonnie Moulder, CEO, and Mary Lynne Hedley, Ph.D., President and COO of TESARO, will present at 1:00 PM ET and will answer questions from investors.
A live webcast of the presentation at the Bank of America conference will be available by visiting the Investors section of the TESARO website at www.tesarobio.com. An archived replay of this webcast will be available on the Company’s website for 14 days following the conferences.

On May 1, 2018 Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company focused on unlocking the full potential of biologic therapies by mitigating unwanted immunogenicity, reported that members of the Selecta management team will present at the following investor conferences (Press release, Selecta Biosciences, MAY 1, 2018, View Source [SID1234525928]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The 43rd Annual Deutsche Bank Health Care Conference – 1.30 p.m. ET on Tuesday, May 8, 2018 in Boston.
UBS Global Healthcare Conference – 9:00 a.m. ET on Wednesday, May 23, 2018 in New York City.
Live and archived webcasts of the presentations will be available on the Investors & Media section of the Selecta website at www.selectabio.com.

On May 1, 2018 Sangamo Therapeutics, Inc. (Nasdaq: SGMO) reported that the company will release its first quarter 2018 financial results before the market opens on Tuesday, May 8, 2018 (Press release, Sangamo Therapeutics, MAY 1, 2018, View Source [SID1234525926]). The press release will be followed by a conference call at 8:00 a.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review its financial results and provide a business update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call dial-in numbers are (877) 377-7553 for domestic callers and (678) 894-3968 for international callers. The conference ID number for the call is 1194369. Participants may access the live webcast via a link on the Sangamo Therapeutics website in the Investors and Media section under Events and Presentations. A conference call replay will be available for one week following the conference call. The conference call replay numbers for domestic and international callers are (855) 859-2056 and (404) 537-3406, respectively. The conference ID number for the replay is 1194369.

On May 1, 2018 RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (sd-rxRNA) therapeutic platform, reported that it will present at the 2018 New York Oncology Investment Conference being held May 8-9, 2018 in New York City (Press release, RXi Pharmaceuticals, MAY 1, 2018, View Source [SID1234525925]). This conference is designed specifically for life science impact investors and provides an intimate setting with a highly screened group of companies and key opinion leaders in the field of oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, May 8, 2018
Time:12:00 p.m. EDT
Presenter: Dr. Karen Bulock, Vice President of Research
Location: Offices of Wilson Sonsini Goodrich & Rosati in New York City

Dr. Bulock will highlight the Company’s sd-rxRNA platform and the ongoing internal and external programs that leverage the self-delivering attributes of its therapeutic compounds in the development of cell-based therapies to treat cancer.

The presentation will be available under the "Investors – Events and Presentations" section of the Company’s website, www.rxipharma.com, approximately 1 hour following the presentation.